Wastewater Partnerships Ceres has established a wastewater-based epidemiology network with Emory Healthcare and Biobot Analytics, supported by NIH RADx funding, creating ready-made channels to offer Nanotrap sample preparation products to public health labs and research centers.

Product Line Expansion In 2022 Ceres expanded its portfolio with Nanotrap Microbiome B Particles and Nanotrap Enhancement Reagent 3, presenting opportunities to cross-sell to existing customers and to laboratories seeking more robust sample processing for microbiome and diagnostic workflows.

Public Health Focus With a focus on underserved populations and settings like correctional facilities and long-term care facilities, Ceres' wastewater surveillance initiatives align with public health buyers and government programs seeking scalable, cost-effective testing solutions.

Clinical Diagnostics Enablement Nanotrap technology improves sensitivity and accuracy across research and clinical diagnostic platforms, enabling hospitals and reference labs to detect low-abundance biomarkers for cancer, cardiovascular, and infectious diseases.

Strategic Growth As a mid-sized private company with a growing revenue footprint and a small but capable team, Ceres can scale through channel partnerships, geographic expansion from its Manassas base, and co-funded collaborations with research institutions.